ORYZFOTCHealthcare · Biotechnology

Oryzon Genomics S.A.

$3.65+9.28%(+$0.31)

TickerSpark Score

58/100

Mixed

Valuation

Profitability

Growth

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ORYZF research report →

52-Week Range46% of range

Low $3.03

Current $3.65

High $4.38

Companywww.oryzon.com

Oryzon Genomics S. A. , a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders.

CEO: Carlos Manuel Buesa Arjol
IPO: 2020
Employees: 47
HQ: Cornellà de Llobregat, ES

Price Chart

+20.46% · this period

Valuation

Market Cap: $282.92M
P/E: -108.76
P/S: 0.00
P/B: 2.18
EV/EBITDA: -21.48
Div Yield: 0.00%

Profitability

Gross Margin: 0.00%
Op Margin: 0.00%
Net Margin: 0.00%
ROE: -2.09%
ROIC: -3.00%

Growth & Income

Revenue: $0 · -100.00%
Net Income: $-2,604,492 · 28.94%
EPS: $-0.04 · 38.16%
Op Income: $-6,416,519.5
FCF YoY: 81.98%

Performance & Tape

52W High: $4.38
52W Low: $3.03
50D MA: $3.34
200D MA: $3.43
Beta: -0.12
Avg Volume: 72

Get TickerSpark's AI analysis on ORYZF

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime